Startups

Director or Senior Director, CMC Program Management

Kymera Therapeutics · Watertown, MA · On-site

← All jobs
About Kymera Therapeutics

Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation. Backed by Bessemer.

About the role

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

What they're looking for

  • CMC program/project management experience for oral small molecule programs, with experience advancing programs through Phase 3, NDA/MAA submission, process validation, and approval
  • Broad CMC technical knowledge spanning drug substance, drug product, and analytical development, with sufficient depth to challenge assumptions, assess risk, and support troubleshooting
  • Prior experience in working with CDMOs and CROs, technology transfer, GMP manufacturing, and commercial supply management
  • Working knowledge/experience in global CMC regulatory requirements and expectations (FDA, EMA, ICH), GMP/GLP compliance, and inspection readiness
  • Proven ability to manage complex, cross-functional programs and translate technical concepts into executable plans
  • Exceptional communication, organizational skills and attention to detail
More about this role

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn .

  • PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
  • COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
  • BELONG : We recognize our differences, inviting...

Read the full posting on Kymera Therapeutics's site ↗

Technical Operations & Quality

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.